<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02661490</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-204</org_study_id>
    <secondary_id>U1111-1162-4913</secondary_id>
    <nct_id>NCT02661490</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population</brief_title>
  <official_title>A Phase II, Randomized, Double-blind, Safety and Immunogenicity Trial of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in Healthy Elderly Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to further develop a formulation and dose regimen of the
      norovirus GI.1/GII.4 bivalent virus-like particle (VLP) vaccine that is immunogenic and safe
      in an elderly population aged 60 years and above.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The vaccine being tested in this study is called norovirus GI.1/GII.4 bivalent virus-like
      particle (VLP) vaccine adjuvanted with aluminum hydroxide (Formulation A) or adjuvanted with
      monophosphoryl lipid A (MPL) and aluminum hydroxide (Formulation B). Two norovirus vaccine
      formulations are being tested to select for further development the formulation that will
      generate an optimal specific antibody response that may provide protection against norovirus
      and is safe in a population aged 60 years and above. This study will look at side effects and
      the level of antibodies to norovirus formed in people who will be injected with different
      formulations of the norovirus vaccine candidate.

      The study will enroll approximately 325 patients. Participants will be randomly assigned (by
      chance) to one of five treatment groups.

        -  Norovirus GI.1/GII.4 bivalent VLP vaccine (Formulation A) 1-dose, participants ≥ 60
           years

        -  Norovirus GI.1/GII.4 bivalent VLP vaccine (Formulation A) 2-dose, participants ≥ 60
           years

        -  Norovirus GI.1/GII.4 bivalent VLP vaccine (Formulation B) 1-dose, participants ≥ 60
           years

        -  Norovirus GI.1/GII.4 bivalent VLP vaccine (Formulation B) 2-dose, participants ≥ 60
           years

        -  Norovirus GI.1/GII.4 bivalent VLP vaccine (Formulation A) 1-dose, participants 18 to 49
           years All participants in the age of 60 years and older will be administered either NoV
           vaccine (Formulation A or B) or placebo on Day 1 and NoV vaccine (Formulation A or B) on
           Day 29 of the study. In order to keep the treatment arms undisclosed to the patient and
           the doctor, those randomized to the one dose groups will receive a dose of placebo (this
           is a saline solution that has no active ingredient) on Day 1 followed by the NoV vaccine
           on Day 29. Those randomized to 2 doses with receive the NoV vaccine on Day 1 and Day 29.
           In case of an urgent medical need a participant can be unblinded.

      Adults aged 18 to 49 will receive placebo on Day 1 followed by NoV vaccine Formulation A on
      Day 29.

      Participants will be asked to record any reactions/ symptoms that may be related or not to
      the vaccine in a diary card for 28 days after each vaccination.

      This multi-center trial will be conducted in the United States of America. The overall time
      to participate in this study is up to 393 days. Participants will make multiple visits to the
      clinic including a final follow-up visit on Day 393.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2016</start_date>
  <completion_date type="Actual">September 29, 2017</completion_date>
  <primary_completion_date type="Actual">October 28, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 and GII.4 Virus Like Particles (VLP) as Measured by Histoblood Group Antigen (HBGA) Blocking Assay on Day 57</measure>
    <time_frame>Day 57</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</measure>
    <time_frame>Within 7 days of first vaccination on Day 1</time_frame>
    <description>Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema swelling and induration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</measure>
    <time_frame>Within 7 days of second vaccination on Day 29</time_frame>
    <description>Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema, swelling and induration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</measure>
    <time_frame>Within 7 days of first vaccination on Day 1</time_frame>
    <description>Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</measure>
    <time_frame>Within 7 days of second vaccination on Day 29</time_frame>
    <description>Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Elevated Body Temperature ≥38°C (Defined as Fever) for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</measure>
    <time_frame>Within 7 days of first vaccination on Day 1</time_frame>
    <description>The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Elevated Body Temperature ≥38°C (Defined as Fever) for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</measure>
    <time_frame>Within 7 days of second vaccination on Day 29</time_frame>
    <description>The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With At Least One Unsolicited Adverse Event (AE) Within 28-days After First Vaccination on Day 1</measure>
    <time_frame>Within 28 days of first vaccination on Day 1</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With At Least One Unsolicited Adverse Event (AE) Within 28-days After Second Vaccination on Day 29</measure>
    <time_frame>Within 28 days of second vaccination on Day 29</time_frame>
    <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With At Least One Serious Adverse Event (SAE)</measure>
    <time_frame>From first vaccination up to Day 393</time_frame>
    <description>An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 VLP and GII.4 VLP as Measured by HBGA Blocking Assay</measure>
    <time_frame>Days 8, 29, 36, 211 and 393</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer (GMT) GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMT GI.1 VLP antibody titers measured by HBGA blocking assay are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMT of anti-norovirus GII.4 VLP antibody titers measured by HBGA blocking assay are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Fold Rise (GMFR) of Anti-norovirus GI.1 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMFR of anti-norovirus GI.1 VLP antibody titers measured by HBGA blocking assay are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMFR of anti-norovirus GII.4 VLP antibody titers measured by HBGA blocking assay are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 VLP and GII.4 VLP as Measured by Total Immunoglobulin-Enzyme-linked Immunosorbent Assay (Pan-Ig ELISA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP measured by Pan-Ig ELISA are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>Percentage of participants with a 4-Fold rise or greater in serum anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMT of anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMT of anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMFR of anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</measure>
    <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
    <description>GMFR of anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least One Adverse Event of Special Interest (AESI)</measure>
    <time_frame>From first vaccination up to Day 393</time_frame>
    <description>AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With At Least One Adverse Event (AE) Leading to Participant's Withdrawal From the Study</measure>
    <time_frame>From first vaccination up to Day 393</time_frame>
    <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination of treatment, because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">320</enrollment>
  <condition>Norovirus</condition>
  <arm_group>
    <arm_group_label>Arm 1: NoV Vaccine Formulation A _1-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: NoV Vaccine Formulation A _2-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: NoV Vaccine Formulation B_1-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4: NoV Vaccine Formulation B_2-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5: NoV Vaccine Formulation A_1-Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Norovirus GI.1/GII.4 Bivalent VLP Vaccine</intervention_name>
    <description>Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection</description>
    <arm_group_label>Arm 1: NoV Vaccine Formulation A _1-Dose</arm_group_label>
    <arm_group_label>Arm 2: NoV Vaccine Formulation A _2-Dose</arm_group_label>
    <arm_group_label>Arm 5: NoV Vaccine Formulation A_1-Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% sodium chloride (saline)</intervention_name>
    <description>norovirus bivalent placebo-matching vaccine</description>
    <arm_group_label>Arm 1: NoV Vaccine Formulation A _1-Dose</arm_group_label>
    <arm_group_label>Arm 3: NoV Vaccine Formulation B_1-Dose</arm_group_label>
    <arm_group_label>Arm 5: NoV Vaccine Formulation A_1-Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Norovirus GI.1/GII.4 Bivalent VLP Vaccine</intervention_name>
    <description>Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection</description>
    <arm_group_label>Arm 3: NoV Vaccine Formulation B_1-Dose</arm_group_label>
    <arm_group_label>Arm 4: NoV Vaccine Formulation B_2-Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is aged 18 to 49 years, or 60 years and older at the time of enrollment;

          2. Participants who are in good health, or in stable health status with no exclusionary
             medical or neuropsychiatric conditions at the time of entry into the trial as
             determined by medical history, physical examination (including vital signs) and
             clinical judgment of the Investigator;

          3. Participant signs and dates a written, Informed Consent Form (ICF) and any required
             privacy authorization prior to the initiation of any trial procedures, after the
             nature of the trial has been explained according to local regulatory requirements;

          4. Participants who can comply with trial procedures and are available for the duration
             of follow-up.

        Exclusion Criteria:

          1. Has a known hypersensitivity or allergy to any of the Norovirus (NoV) GI.1/GII.4
             Bivalent virus-like particle (VLP) Vaccine components;

          2. Has a clinically significant active infection (as assessed by the Investigator) or
             body temperature ≥38°C/100.4°F within 3 days of the intended date of vaccination;

          3. Participants with the presence of significant acute or chronic, uncontrolled medical
             or neuropsychiatric illness. Uncontrolled was defined as:

             Requiring institution of new medical or surgical treatment within 3 months prior to
             immunization, or Requiring a change in medication dosage in the 3 months prior to
             immunization due to uncontrolled symptoms or drug toxicity (elective dosage
             adjustments in stable participants were acceptable), or Hospitalization or an event
             fulfilling the definition of a serious adverse event within 3 months prior
             immunization.

          4. Has any unstable medical or neuropsychiatric condition, which in the Investigator's
             opinion poses a risk of unusual magnitude for the participant's age group of
             hospitalization, death, or an event meeting the definition of a serious adverse event
             within 2 months of immunization. The intent of this criterion is to recognize and
             allow for the frequent existence of significant health concerns in this population;
             but exclude those participants who are experiencing an acute decline in health status;

          5. Has any medical or neuropsychiatric condition, which in the Investigator's opinion,
             rendered the participant incompetent to provide informed consent or unable to provide
             valid safety observations and reports;

          6. Has behavioral or cognitive impairment or psychiatric disease that, in the opinion of
             the Investigator, may interfere with the participant's ability to participate in the
             trial;

          7. Participants with any history of progressive or severe neurologic disorder, history of
             seizure, or history of neuro-inflammatory disease (e.g. Guillain-Barre syndrome);

          8. Participants with history or any illness that, in the opinion of the Investigator,
             might interfere with the results of the trial or pose additional risk to the
             participants due to participation in the trial;

          9. Has known or suspected autoimmune disease;

         10. Has known or suspected impairment/alteration of immune function, including:

             Chronic use of oral steroids (Equivalent to 20 mg/day prednisone ≥ 12 weeks/≥ 2 mg/kg
             body weight/day prednisone ≥ 2 weeks) within 60 days prior to Day 1 (use of inhaled,
             intranasal, or topical corticosteroids is allowed).

             Receipt of parenteral steroids (Equivalent to 20 mg/day prednisone ≥ 12 weeks/≥ 2
             mg/kg body weight/day prednisone ≥ 2 weeks) within 60 days prior to Day 1.

             Receipt of immunosuppressive therapy within 3 months prior to Day 1. Receipt of
             immunostimulants within 60 days prior to Day 1. Receipt of parenteral, epidural or
             intra-articular immunoglobulin preparation, blood products, and/or plasma derivatives
             within 3 months prior to Day 1 or planned during the full length of the trial.

             Human Immunodeficiency Virus (HIV) infection or HIV-related disease. Genetic
             immunodeficiency.

         11. Has abnormalities of splenic or thymic function;

         12. Has any significant disorder of coagulation or treatment with anticoagulant therapy
             that would increase the risk of intramuscular (IM) injection. Persons receiving
             prophylactic antiplatelet medication such as low dose of acetylsalicylic acid are
             eligible;

         13. Has any serious chronic or progressive disease according to judgment of the
             Investigator: cancer (malignancy other than resolved/excised skin lesion), insulin
             dependent Type I diabetes (Type II diabetes is accepted), cardiac, renal or hepatic
             disease;

         14. Has body mass index (BMI) greater than or equal to 35 kg/m^2 (= weight in kg/[height
             in meters^2]);

         15. Is participating in any clinical trial with another investigational product 30 days
             prior to first trial visit or intent to participate in another clinical trial at any
             time during the conduct of this trial;

         16. Participants who received any other vaccines within 14 days (for inactivated vaccines)
             or 28 days (for live vaccines) prior to enrollment in this trial or who are planning
             to receive any vaccine within 28 days of investigational vaccine administration;

         17. Participants involved in trial conduct or their first degree relatives;

         18. Has history of substance or alcohol abuse within the past 2 years;

         19. Females who are pregnant or breastfeeding;

         20. If female of childbearing potential, sexually active with a male partner who has not
             been sterilized, and has not used any of the &quot;acceptable contraceptive methods&quot; for at
             least 2 months prior to trial entry:

             Of childbearing potential is defined as status post onset of menarche and not meeting
             any of the following conditions: menopausal for at least 2 years, status after
             bilateral tubal ligation for at least 1 year, status after bilateral oophorectomy, or
             status after hysterectomy.

             Acceptable birth control methods are defined as one or more of the following: i.
             Hormonal contraceptive (such as oral, injection, transdermal patch, implant, cervical
             ring); ii. Barrier (condom with spermicide or diaphragm with spermicide) each and
             every time during intercourse; iii. Intrauterine device (IUD); iv. Monogamous
             relationship with vasectomized partner. Partner must have been vasectomized for at
             least six months prior to the participants' trial entry.

         21. If female of childbearing potential and sexually active, refusal to use an &quot;acceptable
             contraceptive method&quot; from Day 1 and throughout the duration of the trial. In
             addition, they must be advised not to donate ova during this period;

         22. Females with any positive or indeterminate pregnancy test.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director Clinical Science</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Simon Williamson Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fountain Hills Family Practice, P.C.</name>
      <address>
        <city>Fountain Hills</city>
        <state>Arizona</state>
        <zip>85268</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Family Medicine</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johnson County Clin-Trials</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Louis University, School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Research Inc.</name>
      <address>
        <city>Endwell</city>
        <state>New York</state>
        <zip>13760</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Childrens Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Group Health Research Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>January 8, 2016</study_first_submitted>
  <study_first_submitted_qc>January 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2016</study_first_posted>
  <results_first_submitted>April 22, 2020</results_first_submitted>
  <results_first_submitted_qc>April 22, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2020</results_first_posted>
  <last_update_submitted>April 22, 2020</last_update_submitted>
  <last_update_submitted_qc>April 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Norovirus</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda makes patient-level, de-identified data sets and associated documents available for all interventional studies after applicable marketing approvals and commercial availability have been received (or program is completely terminated), an opportunity for the primary publication of the research and final report development has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 2, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02661490/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 16, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/90/NCT02661490/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 10 investigative sites in United States from 1 February 2016 to 31 October 2017.</recruitment_details>
      <pre_assignment_details>Healthy elderly volunteers were enrolled and randomized in 1:1:1:1 ratio in 4 arm groups to receive either one or two doses of one of the 2 formulations (A or B) of norovirus (NoV) GI.1/GII4 bivalent virus like particle (VLP) vaccine or placebo. Healthy young adults received both placebo and formulation A.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
          <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
          <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
        </group>
        <group group_id="P3">
          <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
          <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
        </group>
        <group group_id="P4">
          <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
          <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
        </group>
        <group group_id="P5">
          <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
          <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="70"/>
                <participants group_id="P4" count="71"/>
                <participants group_id="P5" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized Set included all randomized participants regardless of whether any study vaccine (NoV VLP vaccine or placebo) was received.</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
          <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
          <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
        </group>
        <group group_id="B3">
          <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
          <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
        </group>
        <group group_id="B4">
          <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
          <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
        </group>
        <group group_id="B5">
          <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
          <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="76"/>
            <count group_id="B2" value="74"/>
            <count group_id="B3" value="72"/>
            <count group_id="B4" value="72"/>
            <count group_id="B5" value="26"/>
            <count group_id="B6" value="320"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Data is reported for elderly participants only.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.0" spread="9.14"/>
                    <measurement group_id="B2" value="77.4" spread="9.32"/>
                    <measurement group_id="B3" value="76.7" spread="9.22"/>
                    <measurement group_id="B4" value="77.7" spread="9.07"/>
                    <measurement group_id="B6" value="77.4" spread="9.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <population>Data is reported for young adult participants only.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="26"/>
                    <count group_id="B6" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="34.6" spread="8.46"/>
                    <measurement group_id="B6" value="34.6" spread="8.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="26"/>
                    <count group_id="B6" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="40"/>
                    <measurement group_id="B4" value="40"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="32"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="26"/>
                    <count group_id="B6" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="301"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="26"/>
                    <count group_id="B6" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="69"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="70"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="299"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="26"/>
                    <count group_id="B6" value="320"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="74"/>
                    <measurement group_id="B3" value="72"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Data is reported for elderly participants only.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="166.8" spread="9.95"/>
                    <measurement group_id="B2" value="167.3" spread="9.52"/>
                    <measurement group_id="B3" value="168.0" spread="9.17"/>
                    <measurement group_id="B4" value="167.4" spread="10.26"/>
                    <measurement group_id="B6" value="167.3" spread="9.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <population>Data is reported for young adult participants only for whom data for height was available at Baseline.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="25"/>
                    <count group_id="B6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="169.4" spread="11.42"/>
                    <measurement group_id="B6" value="169.4" spread="11.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Data is reported for elderly participants only.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.56" spread="14.376"/>
                    <measurement group_id="B2" value="73.76" spread="13.804"/>
                    <measurement group_id="B3" value="77.26" spread="14.404"/>
                    <measurement group_id="B4" value="74.34" spread="13.965"/>
                    <measurement group_id="B6" value="75.22" spread="14.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <population>Data is reported for young adult participants only for whom data for weight was available at Baseline.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="25"/>
                    <count group_id="B6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="78.22" spread="15.357"/>
                    <measurement group_id="B6" value="78.22" spread="15.357"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI=Weight (kg)/height (m^2)</description>
          <population>Data is reported for elderly participants only.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="76"/>
                    <count group_id="B2" value="74"/>
                    <count group_id="B3" value="72"/>
                    <count group_id="B4" value="72"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="294"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.01" spread="3.554"/>
                    <measurement group_id="B2" value="26.28" spread="3.958"/>
                    <measurement group_id="B3" value="27.29" spread="3.899"/>
                    <measurement group_id="B4" value="26.46" spread="3.909"/>
                    <measurement group_id="B6" value="26.76" spread="3.833"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <description>BMI=Weight (kg)/height (m^2)</description>
          <population>Data is reported for young adult participants only for whom data for BMI was available at Baseline.</population>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="25"/>
                    <count group_id="B6" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="27.22" spread="4.481"/>
                    <measurement group_id="B6" value="27.22" spread="4.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 and GII.4 Virus Like Particles (VLP) as Measured by Histoblood Group Antigen (HBGA) Blocking Assay on Day 57</title>
        <time_frame>Day 57</time_frame>
        <population>Per Protocol Set (PPS) included all participants in the Full Analysis Set (FAS), who receive the planned vaccination [both doses of vaccine, i.e. Norovirus (NoV) VLP vaccine or placebo], and did not have major protocol violations. Overall number of participants analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 and GII.4 Virus Like Particles (VLP) as Measured by Histoblood Group Antigen (HBGA) Blocking Assay on Day 57</title>
          <population>Per Protocol Set (PPS) included all participants in the Full Analysis Set (FAS), who receive the planned vaccination [both doses of vaccine, i.e. Norovirus (NoV) VLP vaccine or placebo], and did not have major protocol violations. Overall number of participants analyzed is the number of participants with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="65"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.3" lower_limit="30.6" upper_limit="54.6"/>
                    <measurement group_id="O2" value="41.5" lower_limit="29.4" upper_limit="54.4"/>
                    <measurement group_id="O3" value="56.5" lower_limit="43.3" upper_limit="69.0"/>
                    <measurement group_id="O4" value="63.6" lower_limit="50.9" upper_limit="75.1"/>
                    <measurement group_id="O5" value="45.8" lower_limit="25.6" upper_limit="67.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</title>
        <description>Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema swelling and induration.</description>
        <time_frame>Within 7 days of first vaccination on Day 1</time_frame>
        <population>Safety Analysis Set (SAF) included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Number analyzed is the number of participants with evaluable data for the specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</title>
          <description>Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema swelling and induration.</description>
          <population>Safety Analysis Set (SAF) included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Number analyzed is the number of participants with evaluable data for the specific category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Local AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6"/>
                    <measurement group_id="O2" value="26.0"/>
                    <measurement group_id="O3" value="15.3"/>
                    <measurement group_id="O4" value="34.7"/>
                    <measurement group_id="O5" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="23.3"/>
                    <measurement group_id="O3" value="9.7"/>
                    <measurement group_id="O4" value="34.7"/>
                    <measurement group_id="O5" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="4.2"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="1.4"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</title>
        <description>Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema, swelling and induration.</description>
        <time_frame>Within 7 days of second vaccination on Day 29</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Local Adverse Events (AEs) at Injection Site for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</title>
          <description>Solicited local AEs at the injection site that occurred within 7 days after each vaccination were collected using a diary and included pain, erythema, swelling and induration.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any Solicited Local AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.0"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="38.2"/>
                    <measurement group_id="O4" value="39.4"/>
                    <measurement group_id="O5" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="21.7"/>
                    <measurement group_id="O3" value="38.2"/>
                    <measurement group_id="O4" value="37.9"/>
                    <measurement group_id="O5" value="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythema</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="3.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Induration</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="1.5"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</title>
        <description>Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.</description>
        <time_frame>Within 7 days of first vaccination on Day 1</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Number analyzed is the number of participants with evaluable data for the specific category.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</title>
          <description>Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Number analyzed is the number of participants with evaluable data for the specific category.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited systemic AEs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.9"/>
                    <measurement group_id="O2" value="34.2"/>
                    <measurement group_id="O3" value="30.6"/>
                    <measurement group_id="O4" value="44.4"/>
                    <measurement group_id="O5" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.4"/>
                    <measurement group_id="O2" value="24.7"/>
                    <measurement group_id="O3" value="9.7"/>
                    <measurement group_id="O4" value="27.8"/>
                    <measurement group_id="O5" value="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="13.7"/>
                    <measurement group_id="O3" value="11.1"/>
                    <measurement group_id="O4" value="20.8"/>
                    <measurement group_id="O5" value="16.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="8.2"/>
                    <measurement group_id="O3" value="6.9"/>
                    <measurement group_id="O4" value="6.9"/>
                    <measurement group_id="O5" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="2.8"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="76"/>
                    <count group_id="O2" value="73"/>
                    <count group_id="O3" value="72"/>
                    <count group_id="O4" value="72"/>
                    <count group_id="O5" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="6.8"/>
                    <measurement group_id="O3" value="8.3"/>
                    <measurement group_id="O4" value="18.1"/>
                    <measurement group_id="O5" value="8.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</title>
        <description>Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.</description>
        <time_frame>Within 7 days of second vaccination on Day 29</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Solicited Systemic Adverse Events (AEs) for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</title>
          <description>Solicited systemic AEs that occurred within 7 days after each vaccination were collected using a diary and included headache, fatigue, myalgia, arthralgia, vomiting, and diarrhea.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any solicited systemic AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="20.3"/>
                    <measurement group_id="O3" value="20.6"/>
                    <measurement group_id="O4" value="28.8"/>
                    <measurement group_id="O5" value="16.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="5.9"/>
                    <measurement group_id="O4" value="6.1"/>
                    <measurement group_id="O5" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatigue</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3"/>
                    <measurement group_id="O2" value="15.9"/>
                    <measurement group_id="O3" value="13.2"/>
                    <measurement group_id="O4" value="15.2"/>
                    <measurement group_id="O5" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myalgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8"/>
                    <measurement group_id="O2" value="5.8"/>
                    <measurement group_id="O3" value="7.4"/>
                    <measurement group_id="O4" value="13.6"/>
                    <measurement group_id="O5" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Arthralgia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                    <measurement group_id="O2" value="7.2"/>
                    <measurement group_id="O3" value="4.4"/>
                    <measurement group_id="O4" value="6.1"/>
                    <measurement group_id="O5" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diarrhea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4"/>
                    <measurement group_id="O2" value="4.3"/>
                    <measurement group_id="O3" value="2.9"/>
                    <measurement group_id="O4" value="4.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Elevated Body Temperature ≥38°C (Defined as Fever) for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</title>
        <description>The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).</description>
        <time_frame>Within 7 days of first vaccination on Day 1</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Body Temperature ≥38°C (Defined as Fever) for 7-day Period (Including Day of Vaccination) After First Vaccination on Day 1</title>
          <description>The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="72"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="71"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Elevated Body Temperature ≥38°C (Defined as Fever) for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</title>
        <description>The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).</description>
        <time_frame>Within 7 days of second vaccination on Day 29</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Elevated Body Temperature ≥38°C (Defined as Fever) for 7-day Period (Including Day of Vaccination) After Second Vaccination on Day 29</title>
          <description>The body temperature measurement was performed using the thermometer for 7 days after each vaccination. The highest body temperature observed each day was recorded on the diary card. An elevated temperature is ≥ 38 °C or 100.4°F (considered as fever).</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is the number of participants with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With At Least One Unsolicited Adverse Event (AE) Within 28-days After First Vaccination on Day 1</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Within 28 days of first vaccination on Day 1</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Unsolicited Adverse Event (AE) Within 28-days After First Vaccination on Day 1</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.9"/>
                    <measurement group_id="O2" value="28.4"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="26.4"/>
                    <measurement group_id="O5" value="20.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With At Least One Unsolicited Adverse Event (AE) Within 28-days After Second Vaccination on Day 29</title>
        <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.</description>
        <time_frame>Within 28 days of second vaccination on Day 29</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is number of participants with data available for analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Unsolicited Adverse Event (AE) Within 28-days After Second Vaccination on Day 29</title>
          <description>An AE is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo). Overall number of participants analyzed is number of participants with data available for analyses.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.2"/>
                    <measurement group_id="O2" value="18.8"/>
                    <measurement group_id="O3" value="25.0"/>
                    <measurement group_id="O4" value="30.3"/>
                    <measurement group_id="O5" value="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With At Least One Serious Adverse Event (SAE)</title>
        <description>An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
        <time_frame>From first vaccination up to Day 393</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Serious Adverse Event (SAE)</title>
          <description>An SAE is any untoward medical occurrence that at any dose results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or is medically important due to other reasons than the above mentioned criteria.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.2"/>
                    <measurement group_id="O2" value="12.2"/>
                    <measurement group_id="O3" value="23.6"/>
                    <measurement group_id="O4" value="12.5"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 VLP and GII.4 VLP as Measured by HBGA Blocking Assay</title>
        <time_frame>Days 8, 29, 36, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 VLP and GII.4 VLP as Measured by HBGA Blocking Assay</title>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="33.8" lower_limit="22.6" upper_limit="46.6"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="55.4" lower_limit="42.5" upper_limit="67.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="40.9" lower_limit="29.0" upper_limit="53.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="54.5" lower_limit="41.8" upper_limit="66.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.4" lower_limit="16.7" upper_limit="38.1"/>
                    <measurement group_id="O2" value="45.5" lower_limit="33.1" upper_limit="58.2"/>
                    <measurement group_id="O3" value="34.4" lower_limit="22.9" upper_limit="47.3"/>
                    <measurement group_id="O4" value="63.6" lower_limit="50.9" upper_limit="75.1"/>
                    <measurement group_id="O5" value="43.5" lower_limit="23.2" upper_limit="65.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.5" lower_limit="8.0" upper_limit="26.0"/>
                    <measurement group_id="O2" value="18.2" lower_limit="9.8" upper_limit="29.6"/>
                    <measurement group_id="O3" value="28.1" lower_limit="17.6" upper_limit="40.8"/>
                    <measurement group_id="O4" value="30.3" lower_limit="19.6" upper_limit="42.9"/>
                    <measurement group_id="O5" value="8.7" lower_limit="1.1" upper_limit="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" lower_limit="6.1" upper_limit="23.0"/>
                    <measurement group_id="O2" value="10.9" lower_limit="4.5" upper_limit="21.2"/>
                    <measurement group_id="O3" value="19.0" lower_limit="10.2" upper_limit="30.9"/>
                    <measurement group_id="O4" value="16.9" lower_limit="8.8" upper_limit="28.3"/>
                    <measurement group_id="O5" value="13.0" lower_limit="2.8" upper_limit="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GI.1 VLP Antibody Titers (HBGA)</title>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GI.1 VLP Antibody Titers (HBGA)</title>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="63.1" lower_limit="50.2" upper_limit="74.7"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="76.9" lower_limit="64.8" upper_limit="86.5"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="72.7" lower_limit="60.4" upper_limit="83.0"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="77.3" lower_limit="65.3" upper_limit="86.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.6" lower_limit="43.4" upper_limit="67.3"/>
                    <measurement group_id="O2" value="74.2" lower_limit="62.0" upper_limit="84.2"/>
                    <measurement group_id="O3" value="65.6" lower_limit="52.7" upper_limit="77.1"/>
                    <measurement group_id="O4" value="89.4" lower_limit="79.4" upper_limit="95.6"/>
                    <measurement group_id="O5" value="60.9" lower_limit="38.5" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.8" lower_limit="52.5" upper_limit="75.8"/>
                    <measurement group_id="O2" value="80.0" lower_limit="68.2" upper_limit="88.9"/>
                    <measurement group_id="O3" value="74.2" lower_limit="61.5" upper_limit="84.5"/>
                    <measurement group_id="O4" value="89.4" lower_limit="79.4" upper_limit="95.6"/>
                    <measurement group_id="O5" value="62.5" lower_limit="40.6" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.8" lower_limit="23.0" upper_limit="46.0"/>
                    <measurement group_id="O2" value="57.6" lower_limit="44.8" upper_limit="69.7"/>
                    <measurement group_id="O3" value="54.7" lower_limit="41.7" upper_limit="67.2"/>
                    <measurement group_id="O4" value="57.6" lower_limit="44.8" upper_limit="69.7"/>
                    <measurement group_id="O5" value="26.1" lower_limit="10.2" upper_limit="48.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.7" lower_limit="16.0" upper_limit="37.6"/>
                    <measurement group_id="O2" value="50.0" lower_limit="37.2" upper_limit="62.8"/>
                    <measurement group_id="O3" value="41.3" lower_limit="29.0" upper_limit="54.4"/>
                    <measurement group_id="O4" value="47.7" lower_limit="35.1" upper_limit="60.5"/>
                    <measurement group_id="O5" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</title>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</title>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="54.5" lower_limit="41.8" upper_limit="66.9"/>
                    <measurement group_id="O3" value="1.5" lower_limit="0.0" upper_limit="8.2"/>
                    <measurement group_id="O4" value="69.2" lower_limit="56.6" upper_limit="80.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="59.7" lower_limit="47.0" upper_limit="71.5"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="71.2" lower_limit="58.7" upper_limit="81.7"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" lower_limit="44.7" upper_limit="68.6"/>
                    <measurement group_id="O2" value="62.7" lower_limit="50.0" upper_limit="74.2"/>
                    <measurement group_id="O3" value="53.1" lower_limit="40.2" upper_limit="65.7"/>
                    <measurement group_id="O4" value="71.2" lower_limit="58.7" upper_limit="81.7"/>
                    <measurement group_id="O5" value="78.3" lower_limit="56.3" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.6" lower_limit="55.5" upper_limit="78.2"/>
                    <measurement group_id="O2" value="57.6" lower_limit="44.8" upper_limit="69.7"/>
                    <measurement group_id="O3" value="74.2" lower_limit="61.5" upper_limit="84.5"/>
                    <measurement group_id="O4" value="71.2" lower_limit="58.7" upper_limit="81.7"/>
                    <measurement group_id="O5" value="66.7" lower_limit="44.7" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.4" lower_limit="28.0" upper_limit="51.7"/>
                    <measurement group_id="O2" value="34.8" lower_limit="23.5" upper_limit="47.6"/>
                    <measurement group_id="O3" value="45.3" lower_limit="32.8" upper_limit="58.3"/>
                    <measurement group_id="O4" value="45.5" lower_limit="33.1" upper_limit="58.2"/>
                    <measurement group_id="O5" value="47.8" lower_limit="26.8" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="23.3" upper_limit="46.6"/>
                    <measurement group_id="O2" value="30.8" lower_limit="19.9" upper_limit="43.4"/>
                    <measurement group_id="O3" value="33.3" lower_limit="22.0" upper_limit="46.3"/>
                    <measurement group_id="O4" value="36.9" lower_limit="25.3" upper_limit="49.8"/>
                    <measurement group_id="O5" value="39.1" lower_limit="19.7" upper_limit="61.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer (GMT) GI.1 VLP Antibody Titers (HBGA)</title>
        <description>GMT GI.1 VLP antibody titers measured by HBGA blocking assay are reported.</description>
        <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer (GMT) GI.1 VLP Antibody Titers (HBGA)</title>
          <description>GMT GI.1 VLP antibody titers measured by HBGA blocking assay are reported.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5" lower_limit="20.9" upper_limit="33.6"/>
                    <measurement group_id="O2" value="29.0" lower_limit="22.3" upper_limit="37.7"/>
                    <measurement group_id="O3" value="26.7" lower_limit="20.9" upper_limit="34.2"/>
                    <measurement group_id="O4" value="23.9" lower_limit="19.8" upper_limit="28.8"/>
                    <measurement group_id="O5" value="22.0" lower_limit="15.4" upper_limit="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.6" lower_limit="20.9" upper_limit="33.9"/>
                    <measurement group_id="O2" value="282.4" lower_limit="193.2" upper_limit="412.6"/>
                    <measurement group_id="O3" value="26.5" lower_limit="20.9" upper_limit="33.6"/>
                    <measurement group_id="O4" value="332.3" lower_limit="209.9" upper_limit="526.1"/>
                    <measurement group_id="O5" value="21.7" lower_limit="15.3" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2" lower_limit="20.8" upper_limit="33.0"/>
                    <measurement group_id="O2" value="373.6" lower_limit="266.9" upper_limit="523.0"/>
                    <measurement group_id="O3" value="27.3" lower_limit="21.4" upper_limit="34.8"/>
                    <measurement group_id="O4" value="285.5" lower_limit="192.9" upper_limit="422.6"/>
                    <measurement group_id="O5" value="21.7" lower_limit="15.3" upper_limit="30.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="194.2" lower_limit="130.3" upper_limit="289.4"/>
                    <measurement group_id="O2" value="361.1" lower_limit="266.5" upper_limit="489.2"/>
                    <measurement group_id="O3" value="280.1" lower_limit="184.3" upper_limit="425.7"/>
                    <measurement group_id="O4" value="338.9" lower_limit="247.7" upper_limit="463.7"/>
                    <measurement group_id="O5" value="150.8" lower_limit="75.0" upper_limit="303.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="177.0" lower_limit="124.4" upper_limit="251.9"/>
                    <measurement group_id="O2" value="353.6" lower_limit="268.6" upper_limit="465.6"/>
                    <measurement group_id="O3" value="262.2" lower_limit="180.5" upper_limit="381.0"/>
                    <measurement group_id="O4" value="317.1" lower_limit="238.3" upper_limit="421.9"/>
                    <measurement group_id="O5" value="117.7" lower_limit="63.1" upper_limit="219.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="60.4" upper_limit="110.6"/>
                    <measurement group_id="O2" value="160.5" lower_limit="116.5" upper_limit="221.1"/>
                    <measurement group_id="O3" value="128.3" lower_limit="92.7" upper_limit="177.7"/>
                    <measurement group_id="O4" value="126.7" lower_limit="92.7" upper_limit="173.3"/>
                    <measurement group_id="O5" value="54.1" lower_limit="30.1" upper_limit="97.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.2" lower_limit="43.9" upper_limit="82.5"/>
                    <measurement group_id="O2" value="112.2" lower_limit="80.4" upper_limit="156.5"/>
                    <measurement group_id="O3" value="85.7" lower_limit="61.8" upper_limit="118.9"/>
                    <measurement group_id="O4" value="84.6" lower_limit="60.3" upper_limit="118.5"/>
                    <measurement group_id="O5" value="41.0" lower_limit="23.3" upper_limit="72.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</title>
        <description>GMT of anti-norovirus GII.4 VLP antibody titers measured by HBGA blocking assay are reported.</description>
        <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</title>
          <description>GMT of anti-norovirus GII.4 VLP antibody titers measured by HBGA blocking assay are reported.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.5" lower_limit="48.4" upper_limit="91.4"/>
                    <measurement group_id="O2" value="100.3" lower_limit="70.8" upper_limit="142.2"/>
                    <measurement group_id="O3" value="99.5" lower_limit="67.4" upper_limit="146.8"/>
                    <measurement group_id="O4" value="86.1" lower_limit="60.7" upper_limit="122.2"/>
                    <measurement group_id="O5" value="78.7" lower_limit="43.7" upper_limit="141.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.7" lower_limit="43.8" upper_limit="84.2"/>
                    <measurement group_id="O2" value="694.9" lower_limit="462.6" upper_limit="1043.9"/>
                    <measurement group_id="O3" value="94.1" lower_limit="65.2" upper_limit="135.8"/>
                    <measurement group_id="O4" value="994.9" lower_limit="724.8" upper_limit="1365.8"/>
                    <measurement group_id="O5" value="75.2" lower_limit="41.3" upper_limit="137.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.6" lower_limit="42.0" upper_limit="81.6"/>
                    <measurement group_id="O2" value="787.7" lower_limit="524.9" upper_limit="1182.1"/>
                    <measurement group_id="O3" value="82.8" lower_limit="57.5" upper_limit="119.3"/>
                    <measurement group_id="O4" value="876.1" lower_limit="648.5" upper_limit="1183.6"/>
                    <measurement group_id="O5" value="67.2" lower_limit="38.0" upper_limit="118.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="556.5" lower_limit="354.6" upper_limit="873.2"/>
                    <measurement group_id="O2" value="757.1" lower_limit="526.7" upper_limit="1088.4"/>
                    <measurement group_id="O3" value="733.8" lower_limit="460.0" upper_limit="1170.7"/>
                    <measurement group_id="O4" value="799.4" lower_limit="604.1" upper_limit="1057.9"/>
                    <measurement group_id="O5" value="1234.5" lower_limit="627.3" upper_limit="2429.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="528.0" lower_limit="366.2" upper_limit="761.2"/>
                    <measurement group_id="O2" value="600.6" lower_limit="417.3" upper_limit="864.5"/>
                    <measurement group_id="O3" value="790.8" lower_limit="543.4" upper_limit="1151.0"/>
                    <measurement group_id="O4" value="613.6" lower_limit="475.5" upper_limit="791.8"/>
                    <measurement group_id="O5" value="742.0" lower_limit="406.9" upper_limit="1352.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.0" lower_limit="158.2" upper_limit="311.6"/>
                    <measurement group_id="O2" value="298.9" lower_limit="204.6" upper_limit="436.6"/>
                    <measurement group_id="O3" value="318.6" lower_limit="228.6" upper_limit="444.1"/>
                    <measurement group_id="O4" value="315.9" lower_limit="233.7" upper_limit="427.1"/>
                    <measurement group_id="O5" value="280.3" lower_limit="163.4" upper_limit="480.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188.9" lower_limit="129.7" upper_limit="275.1"/>
                    <measurement group_id="O2" value="249.8" lower_limit="164.4" upper_limit="379.8"/>
                    <measurement group_id="O3" value="265.9" lower_limit="184.4" upper_limit="383.6"/>
                    <measurement group_id="O4" value="278.9" lower_limit="204.9" upper_limit="379.7"/>
                    <measurement group_id="O5" value="223.4" lower_limit="114.5" upper_limit="436.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Fold Rise (GMFR) of Anti-norovirus GI.1 VLP Antibody Titers (HBGA)</title>
        <description>GMFR of anti-norovirus GI.1 VLP antibody titers measured by HBGA blocking assay are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Fold Rise (GMFR) of Anti-norovirus GI.1 VLP Antibody Titers (HBGA)</title>
          <description>GMFR of anti-norovirus GI.1 VLP antibody titers measured by HBGA blocking assay are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="10.1" lower_limit="6.6" upper_limit="15.6"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                    <measurement group_id="O4" value="14.1" lower_limit="9.2" upper_limit="21.6"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.0"/>
                    <measurement group_id="O2" value="13.0" lower_limit="9.1" upper_limit="18.6"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                    <measurement group_id="O4" value="12.0" lower_limit="8.5" upper_limit="16.8"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="4.9" upper_limit="10.9"/>
                    <measurement group_id="O2" value="12.6" lower_limit="9.1" upper_limit="17.4"/>
                    <measurement group_id="O3" value="10.6" lower_limit="7.0" upper_limit="15.9"/>
                    <measurement group_id="O4" value="14.2" lower_limit="10.7" upper_limit="18.8"/>
                    <measurement group_id="O5" value="7.5" lower_limit="3.9" upper_limit="14.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" lower_limit="4.8" upper_limit="9.1"/>
                    <measurement group_id="O2" value="12.1" lower_limit="9.1" upper_limit="16.2"/>
                    <measurement group_id="O3" value="10.0" lower_limit="7.1" upper_limit="14.0"/>
                    <measurement group_id="O4" value="13.3" lower_limit="10.3" upper_limit="17.1"/>
                    <measurement group_id="O5" value="5.3" lower_limit="3.0" upper_limit="9.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.6" upper_limit="4.0"/>
                    <measurement group_id="O2" value="5.5" lower_limit="4.2" upper_limit="7.3"/>
                    <measurement group_id="O3" value="4.8" lower_limit="3.7" upper_limit="6.3"/>
                    <measurement group_id="O4" value="5.3" lower_limit="4.1" upper_limit="6.8"/>
                    <measurement group_id="O5" value="2.4" lower_limit="1.4" upper_limit="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="64"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.4" lower_limit="1.9" upper_limit="3.0"/>
                    <measurement group_id="O2" value="3.9" lower_limit="3.0" upper_limit="5.2"/>
                    <measurement group_id="O3" value="3.2" lower_limit="2.5" upper_limit="4.1"/>
                    <measurement group_id="O4" value="3.5" lower_limit="2.7" upper_limit="4.6"/>
                    <measurement group_id="O5" value="1.8" lower_limit="1.1" upper_limit="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</title>
        <description>GMFR of anti-norovirus GII.4 VLP antibody titers measured by HBGA blocking assay are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Anti-norovirus GII.4 VLP Antibody Titers (HBGA)</title>
          <description>GMFR of anti-norovirus GII.4 VLP antibody titers measured by HBGA blocking assay are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.8" upper_limit="1.0"/>
                    <measurement group_id="O2" value="6.9" lower_limit="4.5" upper_limit="10.5"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.8" upper_limit="1.1"/>
                    <measurement group_id="O4" value="11.6" lower_limit="7.7" upper_limit="17.5"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.8" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.8" upper_limit="1.0"/>
                    <measurement group_id="O2" value="7.9" lower_limit="5.6" upper_limit="11.0"/>
                    <measurement group_id="O3" value="0.8" lower_limit="0.7" upper_limit="1.0"/>
                    <measurement group_id="O4" value="10.2" lower_limit="7.2" upper_limit="14.5"/>
                    <measurement group_id="O5" value="0.9" lower_limit="0.8" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" lower_limit="5.4" upper_limit="13.0"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5.5" upper_limit="10.4"/>
                    <measurement group_id="O3" value="7.3" lower_limit="4.8" upper_limit="11.2"/>
                    <measurement group_id="O4" value="9.3" lower_limit="6.6" upper_limit="13.0"/>
                    <measurement group_id="O5" value="15.1" lower_limit="7.1" upper_limit="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.1" lower_limit="5.8" upper_limit="11.4"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.3" upper_limit="7.8"/>
                    <measurement group_id="O3" value="8.4" lower_limit="6.1" upper_limit="11.7"/>
                    <measurement group_id="O4" value="7.1" lower_limit="5.3" upper_limit="9.6"/>
                    <measurement group_id="O5" value="9.4" lower_limit="4.8" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.6" upper_limit="4.5"/>
                    <measurement group_id="O2" value="3.0" lower_limit="2.2" upper_limit="4.1"/>
                    <measurement group_id="O3" value="3.4" lower_limit="2.5" upper_limit="4.5"/>
                    <measurement group_id="O4" value="3.7" lower_limit="2.8" upper_limit="4.8"/>
                    <measurement group_id="O5" value="3.8" lower_limit="2.2" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" lower_limit="2.3" upper_limit="3.8"/>
                    <measurement group_id="O2" value="2.6" lower_limit="2.0" upper_limit="3.5"/>
                    <measurement group_id="O3" value="2.7" lower_limit="2.1" upper_limit="3.5"/>
                    <measurement group_id="O4" value="3.2" lower_limit="2.4" upper_limit="4.1"/>
                    <measurement group_id="O5" value="3.0" lower_limit="1.7" upper_limit="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 VLP and GII.4 VLP as Measured by Total Immunoglobulin-Enzyme-linked Immunosorbent Assay (Pan-Ig ELISA)</title>
        <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP measured by Pan-Ig ELISA are reported.</description>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 VLP and GII.4 VLP as Measured by Total Immunoglobulin-Enzyme-linked Immunosorbent Assay (Pan-Ig ELISA)</title>
          <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus antibody titers for both GI.1 VLP and GII.4 VLP measured by Pan-Ig ELISA are reported.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="31.8" lower_limit="20.9" upper_limit="44.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="52.3" lower_limit="39.5" upper_limit="64.9"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="47.8" lower_limit="35.4" upper_limit="60.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="62.1" lower_limit="49.3" upper_limit="73.8"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.5" lower_limit="26.4" upper_limit="49.7"/>
                    <measurement group_id="O2" value="49.3" lower_limit="36.8" upper_limit="61.8"/>
                    <measurement group_id="O3" value="39.1" lower_limit="27.1" upper_limit="52.1"/>
                    <measurement group_id="O4" value="63.6" lower_limit="50.9" upper_limit="75.1"/>
                    <measurement group_id="O5" value="69.6" lower_limit="47.1" upper_limit="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" lower_limit="39.9" upper_limit="64.1"/>
                    <measurement group_id="O2" value="43.9" lower_limit="31.7" upper_limit="56.7"/>
                    <measurement group_id="O3" value="58.1" lower_limit="44.8" upper_limit="70.5"/>
                    <measurement group_id="O4" value="62.1" lower_limit="49.3" upper_limit="73.8"/>
                    <measurement group_id="O5" value="62.5" lower_limit="40.6" upper_limit="81.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.8" lower_limit="29.3" upper_limit="53.2"/>
                    <measurement group_id="O2" value="37.9" lower_limit="26.2" upper_limit="50.7"/>
                    <measurement group_id="O3" value="40.6" lower_limit="28.5" upper_limit="53.6"/>
                    <measurement group_id="O4" value="42.4" lower_limit="30.3" upper_limit="55.2"/>
                    <measurement group_id="O5" value="47.8" lower_limit="26.8" upper_limit="69.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.3" lower_limit="14.8" upper_limit="36.0"/>
                    <measurement group_id="O2" value="15.4" lower_limit="7.6" upper_limit="26.5"/>
                    <measurement group_id="O3" value="25.4" lower_limit="15.3" upper_limit="37.9"/>
                    <measurement group_id="O4" value="23.1" lower_limit="13.5" upper_limit="35.2"/>
                    <measurement group_id="O5" value="30.4" lower_limit="13.2" upper_limit="52.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Percentage of participants with a 4-Fold rise or greater in serum anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Percentage of participants with a 4-Fold rise or greater in serum anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="5.0"/>
                    <measurement group_id="O2" value="56.1" lower_limit="43.3" upper_limit="68.3"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="69.2" lower_limit="56.6" upper_limit="80.1"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" lower_limit="0.0" upper_limit="7.5"/>
                    <measurement group_id="O2" value="67.2" lower_limit="54.6" upper_limit="78.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="5.4"/>
                    <measurement group_id="O4" value="80.3" lower_limit="68.7" upper_limit="89.1"/>
                    <measurement group_id="O5" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.7" lower_limit="47.5" upper_limit="71.1"/>
                    <measurement group_id="O2" value="67.2" lower_limit="54.6" upper_limit="78.2"/>
                    <measurement group_id="O3" value="68.8" lower_limit="55.9" upper_limit="79.8"/>
                    <measurement group_id="O4" value="83.3" lower_limit="72.1" upper_limit="91.4"/>
                    <measurement group_id="O5" value="91.3" lower_limit="72.0" upper_limit="98.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" lower_limit="61.4" upper_limit="83.1"/>
                    <measurement group_id="O2" value="65.2" lower_limit="52.4" upper_limit="76.5"/>
                    <measurement group_id="O3" value="83.9" lower_limit="72.3" upper_limit="92.0"/>
                    <measurement group_id="O4" value="84.8" lower_limit="73.9" upper_limit="92.5"/>
                    <measurement group_id="O5" value="87.5" lower_limit="67.6" upper_limit="97.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.0" lower_limit="49.7" upper_limit="73.2"/>
                    <measurement group_id="O2" value="63.6" lower_limit="50.9" upper_limit="75.1"/>
                    <measurement group_id="O3" value="70.3" lower_limit="57.6" upper_limit="81.1"/>
                    <measurement group_id="O4" value="72.7" lower_limit="60.4" upper_limit="83.0"/>
                    <measurement group_id="O5" value="73.9" lower_limit="51.6" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.6" lower_limit="36.4" upper_limit="60.8"/>
                    <measurement group_id="O2" value="41.5" lower_limit="29.4" upper_limit="54.4"/>
                    <measurement group_id="O3" value="52.4" lower_limit="39.4" upper_limit="65.1"/>
                    <measurement group_id="O4" value="60.0" lower_limit="47.1" upper_limit="72.0"/>
                    <measurement group_id="O5" value="60.9" lower_limit="38.5" upper_limit="80.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>Percentage of participants with a 4-fold rise or greater in serum anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="50.0" lower_limit="29.1" upper_limit="70.9"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O4" value="62.5" lower_limit="40.6" upper_limit="81.2"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                    <measurement group_id="O2" value="70.8" lower_limit="48.9" upper_limit="87.4"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="14.8"/>
                    <measurement group_id="O4" value="70.8" lower_limit="48.9" upper_limit="87.4"/>
                    <measurement group_id="O5" value="0.0" lower_limit="0.0" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.8" lower_limit="40.7" upper_limit="64.7"/>
                    <measurement group_id="O2" value="68.7" lower_limit="56.2" upper_limit="79.4"/>
                    <measurement group_id="O3" value="48.4" lower_limit="35.8" upper_limit="61.3"/>
                    <measurement group_id="O4" value="71.2" lower_limit="58.7" upper_limit="81.7"/>
                    <measurement group_id="O5" value="73.9" lower_limit="51.6" upper_limit="89.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.4" lower_limit="58.4" upper_limit="80.7"/>
                    <measurement group_id="O2" value="63.6" lower_limit="50.9" upper_limit="75.1"/>
                    <measurement group_id="O3" value="67.7" lower_limit="54.7" upper_limit="79.1"/>
                    <measurement group_id="O4" value="68.2" lower_limit="55.6" upper_limit="79.1"/>
                    <measurement group_id="O5" value="66.7" lower_limit="44.7" upper_limit="84.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.6" lower_limit="48.3" upper_limit="72.0"/>
                    <measurement group_id="O2" value="53.0" lower_limit="40.3" upper_limit="65.4"/>
                    <measurement group_id="O3" value="50.0" lower_limit="37.2" upper_limit="62.8"/>
                    <measurement group_id="O4" value="53.0" lower_limit="40.3" upper_limit="65.4"/>
                    <measurement group_id="O5" value="52.2" lower_limit="30.6" upper_limit="73.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" lower_limit="23.3" upper_limit="46.6"/>
                    <measurement group_id="O2" value="32.3" lower_limit="21.2" upper_limit="45.1"/>
                    <measurement group_id="O3" value="34.9" lower_limit="23.3" upper_limit="48.0"/>
                    <measurement group_id="O4" value="36.9" lower_limit="25.3" upper_limit="49.8"/>
                    <measurement group_id="O5" value="34.8" lower_limit="16.4" upper_limit="57.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>GMT of anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
        <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>GMT of anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="661.8" lower_limit="508.5" upper_limit="861.2"/>
                    <measurement group_id="O2" value="906.1" lower_limit="622.4" upper_limit="1319.3"/>
                    <measurement group_id="O3" value="838.5" lower_limit="605.8" upper_limit="1160.4"/>
                    <measurement group_id="O4" value="619.7" lower_limit="459.7" upper_limit="835.2"/>
                    <measurement group_id="O5" value="460.3" lower_limit="204.8" upper_limit="1034.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="678.0" lower_limit="519.7" upper_limit="884.5"/>
                    <measurement group_id="O2" value="4534.9" lower_limit="3303.2" upper_limit="6225.8"/>
                    <measurement group_id="O3" value="829.4" lower_limit="603.0" upper_limit="1140.8"/>
                    <measurement group_id="O4" value="6382.8" lower_limit="4698.1" upper_limit="8671.7"/>
                    <measurement group_id="O5" value="455.2" lower_limit="192.4" upper_limit="1076.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668.2" lower_limit="520.4" upper_limit="857.9"/>
                    <measurement group_id="O2" value="7701.1" lower_limit="6141.9" upper_limit="9656.0"/>
                    <measurement group_id="O3" value="791.9" lower_limit="585.7" upper_limit="1070.9"/>
                    <measurement group_id="O4" value="8951.5" lower_limit="7127.3" upper_limit="11242.6"/>
                    <measurement group_id="O5" value="574.0" lower_limit="273.1" upper_limit="1206.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4158.6" lower_limit="3095.1" upper_limit="5587.6"/>
                    <measurement group_id="O2" value="7663.6" lower_limit="6165.5" upper_limit="9525.6"/>
                    <measurement group_id="O3" value="6411.8" lower_limit="4795.4" upper_limit="8573.1"/>
                    <measurement group_id="O4" value="9161.1" lower_limit="7501.2" upper_limit="11188.4"/>
                    <measurement group_id="O5" value="7603.5" lower_limit="4590.2" upper_limit="12595.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6183.5" lower_limit="4929.9" upper_limit="7755.8"/>
                    <measurement group_id="O2" value="7235.1" lower_limit="5945.9" upper_limit="8804.0"/>
                    <measurement group_id="O3" value="8838.3" lower_limit="6928.3" upper_limit="11275.0"/>
                    <measurement group_id="O4" value="8182.2" lower_limit="6751.1" upper_limit="9916.8"/>
                    <measurement group_id="O5" value="8165.5" lower_limit="5659.8" upper_limit="11780.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3945.2" lower_limit="3233.5" upper_limit="4813.6"/>
                    <measurement group_id="O2" value="5161.2" lower_limit="4206.5" upper_limit="6332.6"/>
                    <measurement group_id="O3" value="5406.6" lower_limit="4433.7" upper_limit="6593.0"/>
                    <measurement group_id="O4" value="4882.3" lower_limit="4069.9" upper_limit="5856.9"/>
                    <measurement group_id="O5" value="3523.2" lower_limit="2277.6" upper_limit="5449.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2903.4" lower_limit="2307.1" upper_limit="3653.9"/>
                    <measurement group_id="O2" value="3672.1" lower_limit="2835.7" upper_limit="4755.2"/>
                    <measurement group_id="O3" value="3862.9" lower_limit="3060.2" upper_limit="4876.3"/>
                    <measurement group_id="O4" value="3370.0" lower_limit="2799.0" upper_limit="4057.5"/>
                    <measurement group_id="O5" value="2252.6" lower_limit="1365.3" upper_limit="3716.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMT of Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>GMT of anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
        <time_frame>Baseline (Day 1), Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>GMT of Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>GMT of anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>titer</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="761.9" lower_limit="547.9" upper_limit="1059.7"/>
                    <measurement group_id="O2" value="1054.9" lower_limit="707.8" upper_limit="1572.4"/>
                    <measurement group_id="O3" value="1066.3" lower_limit="719.7" upper_limit="1580.0"/>
                    <measurement group_id="O4" value="897.4" lower_limit="612.3" upper_limit="1315.3"/>
                    <measurement group_id="O5" value="1023.2" lower_limit="543.8" upper_limit="1925.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766.6" lower_limit="553.1" upper_limit="1062.6"/>
                    <measurement group_id="O2" value="4725.5" lower_limit="3479.7" upper_limit="6417.3"/>
                    <measurement group_id="O3" value="1078.9" lower_limit="726.6" upper_limit="1602.0"/>
                    <measurement group_id="O4" value="5691.9" lower_limit="4107.9" upper_limit="7886.7"/>
                    <measurement group_id="O5" value="1054.6" lower_limit="550.6" upper_limit="2020.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="766.8" lower_limit="553.7" upper_limit="1062.0"/>
                    <measurement group_id="O2" value="8105.1" lower_limit="6053.8" upper_limit="10851.6"/>
                    <measurement group_id="O3" value="1017.7" lower_limit="690.1" upper_limit="1500.8"/>
                    <measurement group_id="O4" value="8314.1" lower_limit="6388.3" upper_limit="10820.3"/>
                    <measurement group_id="O5" value="1022.4" lower_limit="574.4" upper_limit="1819.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4587.6" lower_limit="3402.2" upper_limit="6186.0"/>
                    <measurement group_id="O2" value="7911.9" lower_limit="6059.9" upper_limit="10329.8"/>
                    <measurement group_id="O3" value="5411.9" lower_limit="3777.0" upper_limit="7754.5"/>
                    <measurement group_id="O4" value="8025.5" lower_limit="6339.1" upper_limit="10160.5"/>
                    <measurement group_id="O5" value="10084.9" lower_limit="7037.2" upper_limit="14452.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6564.1" lower_limit="5151.3" upper_limit="8364.5"/>
                    <measurement group_id="O2" value="7489.2" lower_limit="5788.1" upper_limit="9690.4"/>
                    <measurement group_id="O3" value="7877.2" lower_limit="5878.8" upper_limit="10554.9"/>
                    <measurement group_id="O4" value="7028.4" lower_limit="5611.6" upper_limit="8803.0"/>
                    <measurement group_id="O5" value="9507.3" lower_limit="7110.9" upper_limit="12711.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3702.0" lower_limit="2913.0" upper_limit="4704.7"/>
                    <measurement group_id="O2" value="4915.8" lower_limit="3676.9" upper_limit="6572.2"/>
                    <measurement group_id="O3" value="4657.8" lower_limit="3510.6" upper_limit="6179.8"/>
                    <measurement group_id="O4" value="4456.2" lower_limit="3493.1" upper_limit="5684.9"/>
                    <measurement group_id="O5" value="4531.5" lower_limit="3194.5" upper_limit="6428.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2216.7" lower_limit="1708.9" upper_limit="2875.3"/>
                    <measurement group_id="O2" value="3151.5" lower_limit="2319.8" upper_limit="4281.5"/>
                    <measurement group_id="O3" value="2807.4" lower_limit="2081.9" upper_limit="3785.8"/>
                    <measurement group_id="O4" value="2853.9" lower_limit="2225.5" upper_limit="3659.7"/>
                    <measurement group_id="O5" value="2969.5" lower_limit="1818.4" upper_limit="4849.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>GMFR of anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Anti-norovirus GI.1 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>GMFR of anti-norovirus GI.1 VLP antibody titers measured by Pan-Ig ELISA are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="5.1" lower_limit="3.7" upper_limit="7.2"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                    <measurement group_id="O4" value="10.3" lower_limit="7.2" upper_limit="14.7"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6.2" upper_limit="11.7"/>
                    <measurement group_id="O3" value="0.9" lower_limit="0.9" upper_limit="1.0"/>
                    <measurement group_id="O4" value="14.4" lower_limit="10.7" upper_limit="19.5"/>
                    <measurement group_id="O5" value="1.2" lower_limit="0.9" upper_limit="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4.5" upper_limit="8.8"/>
                    <measurement group_id="O2" value="8.5" lower_limit="6.1" upper_limit="11.7"/>
                    <measurement group_id="O3" value="7.6" lower_limit="5.5" upper_limit="10.6"/>
                    <measurement group_id="O4" value="14.8" lower_limit="10.9" upper_limit="20.0"/>
                    <measurement group_id="O5" value="17.3" lower_limit="8.4" upper_limit="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.0" lower_limit="6.8" upper_limit="11.9"/>
                    <measurement group_id="O2" value="7.9" lower_limit="5.8" upper_limit="10.8"/>
                    <measurement group_id="O3" value="11.4" lower_limit="8.3" upper_limit="15.6"/>
                    <measurement group_id="O4" value="13.2" lower_limit="9.9" upper_limit="17.7"/>
                    <measurement group_id="O5" value="17.7" lower_limit="8.8" upper_limit="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.8" upper_limit="7.5"/>
                    <measurement group_id="O2" value="5.8" lower_limit="4.3" upper_limit="7.7"/>
                    <measurement group_id="O3" value="6.4" lower_limit="4.9" upper_limit="8.5"/>
                    <measurement group_id="O4" value="7.9" lower_limit="6.2" upper_limit="10.0"/>
                    <measurement group_id="O5" value="8.0" lower_limit="4.1" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" lower_limit="3.6" upper_limit="5.5"/>
                    <measurement group_id="O2" value="4.0" lower_limit="3.1" upper_limit="5.3"/>
                    <measurement group_id="O3" value="4.6" lower_limit="3.6" upper_limit="5.9"/>
                    <measurement group_id="O4" value="5.2" lower_limit="4.2" upper_limit="6.5"/>
                    <measurement group_id="O5" value="5.1" lower_limit="2.6" upper_limit="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>GMFR of Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
        <description>GMFR of anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
        <time_frame>Days 8, 29, 36, 57, 211 and 393</time_frame>
        <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>GMFR of Anti-norovirus GII.4 VLP Antibody Titers (Pan-Ig ELISA)</title>
          <description>GMFR of anti-norovirus GII.4 VLP antibody titers measured by Pan-Ig ELISA are reported. The fold rise was calculated as the ratio of the post-vaccination titer level to the pre-vaccination titer level.</description>
          <population>PPS included all participants in the FAS, who received the planned vaccination (both doses of vaccine, i.e. NoV VLP vaccine or placebo), and did not have major protocol violations. Number analyzed is the number of participants with evaluable data at the given time point.</population>
          <units>ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="72"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="66"/>
                <count group_id="O5" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                    <measurement group_id="O2" value="4.5" lower_limit="3.2" upper_limit="6.2"/>
                    <measurement group_id="O3" value="1.0" lower_limit="1.0" upper_limit="1.1"/>
                    <measurement group_id="O4" value="6.3" lower_limit="4.5" upper_limit="9.0"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="66"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                    <measurement group_id="O2" value="7.7" lower_limit="5.7" upper_limit="10.4"/>
                    <measurement group_id="O3" value="1.0" lower_limit="0.9" upper_limit="1.0"/>
                    <measurement group_id="O4" value="9.3" lower_limit="6.7" upper_limit="12.8"/>
                    <measurement group_id="O5" value="1.0" lower_limit="0.9" upper_limit="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="72"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" lower_limit="4.3" upper_limit="8.4"/>
                    <measurement group_id="O2" value="7.5" lower_limit="5.6" upper_limit="10.0"/>
                    <measurement group_id="O3" value="5.0" lower_limit="3.6" upper_limit="6.9"/>
                    <measurement group_id="O4" value="8.9" lower_limit="6.4" upper_limit="12.4"/>
                    <measurement group_id="O5" value="9.6" lower_limit="5.1" upper_limit="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="62"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="6.4" upper_limit="11.7"/>
                    <measurement group_id="O2" value="6.9" lower_limit="5.2" upper_limit="9.2"/>
                    <measurement group_id="O3" value="8.3" lower_limit="6.2" upper_limit="11.0"/>
                    <measurement group_id="O4" value="7.8" lower_limit="5.8" upper_limit="10.6"/>
                    <measurement group_id="O5" value="9.3" lower_limit="5.1" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 211</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="71"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="64"/>
                    <count group_id="O4" value="66"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.9" lower_limit="3.8" upper_limit="6.3"/>
                    <measurement group_id="O2" value="4.6" lower_limit="3.6" upper_limit="5.9"/>
                    <measurement group_id="O3" value="4.5" lower_limit="3.5" upper_limit="5.7"/>
                    <measurement group_id="O4" value="5.0" lower_limit="3.8" upper_limit="6.4"/>
                    <measurement group_id="O5" value="4.7" lower_limit="3.0" upper_limit="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 393</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="70"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="63"/>
                    <count group_id="O4" value="65"/>
                    <count group_id="O5" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.1" lower_limit="2.4" upper_limit="3.8"/>
                    <measurement group_id="O2" value="3.1" lower_limit="2.4" upper_limit="3.9"/>
                    <measurement group_id="O3" value="2.6" lower_limit="2.1" upper_limit="3.3"/>
                    <measurement group_id="O4" value="3.0" lower_limit="2.4" upper_limit="3.8"/>
                    <measurement group_id="O5" value="3.1" lower_limit="1.9" upper_limit="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least One Adverse Event of Special Interest (AESI)</title>
        <description>AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders.</description>
        <time_frame>From first vaccination up to Day 393</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Adverse Event of Special Interest (AESI)</title>
          <description>AESIs are AEs that are not solicited local or systemic AEs, they are predefined AEs that required close monitoring and prompt reporting to the sponsor. AESI included protocol specified Cardiac Disorders, Gastrointestinal Disorders, Immune System Disorders, Infections and Infestations, Musculoskeletal and Connective Tissue Diseases, Neuroinflammatory Disorders, Renal and Urinary Disorders, Skin Disorders, Thyroid Disorders, Vascular Disorders and Other Disorders.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="2.7"/>
                    <measurement group_id="O3" value="2.8"/>
                    <measurement group_id="O4" value="0.0"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With At Least One Adverse Event (AE) Leading to Participant's Withdrawal From the Study</title>
        <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination of treatment, because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.</description>
        <time_frame>From first vaccination up to Day 393</time_frame>
        <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
            <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
          </group>
          <group group_id="O4">
            <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
            <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
          </group>
          <group group_id="O5">
            <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
            <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With At Least One Adverse Event (AE) Leading to Participant's Withdrawal From the Study</title>
          <description>Withdrawal due to an AE will occur if the participant experiences an AE that requires early termination of treatment, because continued participation imposes an unacceptable risk to the participant's health or the participant is unwilling to continue because of the AE.</description>
          <population>SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="76"/>
                <count group_id="O2" value="74"/>
                <count group_id="O3" value="72"/>
                <count group_id="O4" value="72"/>
                <count group_id="O5" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3"/>
                    <measurement group_id="O2" value="1.4"/>
                    <measurement group_id="O3" value="0.0"/>
                    <measurement group_id="O4" value="1.4"/>
                    <measurement group_id="O5" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All-Cause Mortality and Serious adverse events: From first vaccination (Day 1) through end of study (Day 393); Other adverse events: From any vaccination (Day 1 and Day 29) up to 28 days post vaccination.</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment. SAF included all participants who received at least 1 dose of vaccine (NoV VLP vaccine or placebo).</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: NoV Vaccine Formulation A_1-Dose</title>
          <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, intramuscularly (IM), on Day 1, followed by norovirus (NoV) GI.1 (15 μg)/GII.4 (50 μg) bivalent virus-like particle (VLP) vaccine (Formulation A), IM, on Day 29.</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: NoV Vaccine Formulation A_2-Dose</title>
          <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Days 1 and 29.</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: NoV Vaccine Formulation B_1-Dose</title>
          <description>Participants ≥ 60 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg monophosphoryl lipid A (MPL) (Formulation B), IM, on Day 29.</description>
        </group>
        <group group_id="E4">
          <title>Arm 4: NoV Vaccine Formulation B_2-Dose</title>
          <description>Participants ≥ 60 years of age, 2-dose regimen: Norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine with 15 μg MPL (Formulation B), IM, on Days 1 and 29.</description>
        </group>
        <group group_id="E5">
          <title>Arm 5: NoV Vaccine Formulation A_1-Dose</title>
          <description>Participants 18 to 49 years of age, 1-dose regimen: Norovirus bivalent placebo-matching vaccine, IM, on Day 1, followed by norovirus GI.1 (15 μg)/GII.4 (50 μg) bivalent VLP vaccine (Formulation A), IM, on Day 29.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Atrioventricular block second degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Streptococcal endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Cervical vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bone cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myelodysplastic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Prostate cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhagic stroke</sub_title>
                <description>One treatment-emergent death occurred during treatment with NoV vaccine (formulation B)-2 dose regimen and is not related. Same participant had metabolic encephalopathy and ruptured cerebral aneurysm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Metabolic encephalopathy</sub_title>
                <description>One treatment-emergent death occurred during treatment with NoV vaccine (formulation B)-2 dose regimen and is not related. Same participant had haemorrhagic stroke and ruptured cerebral aneurysm.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Ruptured cerebral aneurysm</sub_title>
                <description>One treatment-emergent death occurred during treatment with NoV vaccine (formulation B)-2 dose regimen and is not related. Same participant had haemorrhagic stroke and metabolic encephalopathy.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <description>One treatment-emergent death occurred during treatment with NoV vaccine (formulation A)-2 dose regimen and is not related.</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <description>One treatment-emergent death occurred during treatment with NoV vaccine (formulation A)-1 dose regimen and is not related.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bladder outlet obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="21" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site bruising</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="76"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="72"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

